Table 2 Metastatic PDAC patient characteristics at the time of blood draw for CTC purification.
From: Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target
ID | Age | Sex | CA19-9 (U/mL) | CEA (ng/mL) | Treatment status |
|---|---|---|---|---|---|
metPDAC01 | 57 | M | 7 | 1.1 | Responding |
metPDAC02 | 49 | F | 117 | 4.8 | Responding |
metPDAC03 | 53 | F | 706 | 5.5 | Progressing |
metPDAC04 | 58 | F | 1307 | 54 | Responding |
metPDAC05 | 66 | F | 7268 | 2.6 | Progressing |
metPDAC06 | 55 | M | 4 | – | Progressing |
metPDAC07 | 60 | M | 354 | 2.9 | Responding |
metPDAC08 | 66 | M | 355 | 3.4 | Responding |
metPDAC09 | 70 | F | 18 | 1.5 | Responding |
metPDAC10 | 75 | F | <1 | 11 | Responding |
metPDAC11 | 49 | M | 32 | 6.4 | Responding |
metPDAC12 | 66 | M | 174 | 19 | Responding |
metPDAC13 | 71 | F | 39 | 5 | Progressing |
metPDAC14 | 70 | F | 54 | 9.9 | Progressing |
metPDAC15 | 71 | F | 49 | 1.6 | Responding |
metPDAC16 | 79 | F | 19 | – | Responding |
metPDAC17 | 67 | M | 593 | 4.2 | Naive |
metPDAC18 | 68 | F | 39 | 2 | Naive |
